Tamoxifen 20 mg

DRUG7 trials

Sponsors

Pfizer, Assiut University, Institut Cancerologie de l'Ouest, Karolinska University Hospital, SOLTI Breast Cancer Research Group

Conditions

Breast CancerBreast CarcinomaBreast NeoplasmsBreast TumorsCancer of BreastDuctal Carcinoma in SituExtensive DiseaseHER2-negative Breast Cancer

Phase 1

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

CompletedNCT01821066

Start: 2013-04-30End: 2013-08-31Updated: 2015-10-08

Phase 2

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

RecruitingNCT04666961

Institut Cancerologie de l'OuestDuctal Carcinoma in Situ, Extensive Disease, Mastectomy

Start: 2021-02-03End: 2033-08-01Target: 262Updated: 2022-04-22

Therapeutic Dose Monitoring (TDM) of Tamoxifen

Karolinska University HospitalBreast Cancer, Breast Carcinoma, Breast Tumors +2

Start: 2022-04-04End: 2023-03-01Updated: 2022-05-25

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

RecruitingNCT05982093

SOLTI Breast Cancer Research GroupBreast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor +1

Start: 2023-02-03End: 2026-12-01Target: 96Updated: 2026-04-24

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

RecruitingNCT06914674

Fudan UniversityPancreatic Neoplasms

Start: 2025-03-20End: 2028-02-28Target: 30Updated: 2025-04-06

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Not yet recruitingNCT07287098

Eli Lilly and CompanyBreast Neoplasms

Start: 2026-05-01End: 2029-12-01Target: 600Updated: 2026-05-22

Unknown Phase

Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen

Assiut UniversityBreast Cancer

Start: 2019-09-01End: 2020-12-31Target: 100Updated: 2019-07-08

Related Papers

Abstract PD10-01: Elacestrant alone or in combination with triptorelin in premenopausal women with ER+/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- PremiÈRe trial

Clinical Cancer Research2026-02-17